Ameritas Investment Partners’s Avita Medical RCEL Stock Holding History

Ameritas Investment Partners’s Portfolio RCEL Stock Details RCEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2,076	Closed	-$7.68K	–	3301
2026 Q1	$7.68K	Hold	2,076	–	–	﹤0.01%	2914
2025 Q4	$7.16K	Hold	2,076	–	–	﹤0.01%	2979
2025 Q3	$10.6K	Hold	2,076	–	–	﹤0.01%	2930
2025 Q2	$11K	Hold	2,076	–	–	﹤0.01%	2949
2025 Q1	$16.9K	Hold	2,076	–	–	﹤0.01%	2627
2024 Q4	$26.6K	Hold	2,076	–	–	﹤0.01%	2511
2024 Q3	$22.3K	Hold	2,076	–	–	﹤0.01%	2596
2024 Q2	$16.4K	Hold	2,076	–	–	﹤0.01%	2699
2024 Q1	$33.3K	Hold	2,076	–	–	﹤0.01%	2346
2023 Q4	$28.5K	Hold	2,076	–	–	﹤0.01%	2424
2023 Q3	$30.3K	Hold	2,076	–	–	﹤0.01%	2346
2023 Q2	$35.3K	Buy	+2,076	New	+$30.5K	﹤0.01%	2243
2022 Q2	–	Sell	-1,872	Closed	-$16K	–	3203
2022 Q1	$16K	Hold	1,872	–	–	﹤0.01%	2650
2021 Q4	$22K	Hold	1,872	–	–	﹤0.01%	2606
2021 Q3	$33K	Hold	1,872	–	–	﹤0.01%	2418
2021 Q2	$38K	Buy	+1,872	New	+$36.9K	﹤0.01%	2368

Other funds holding RCEL

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ameritas Investment Partners's RCEL Position: Q2 2026 in Review

Ameritas Investment Partners sold out of Avita Medical (RCEL) in Q2 2026, closing a stake of 2,076 shares — an estimated $7.68K sold.

Ameritas Investment Partners first reported a position in RCEL in Q2 2021 and held it in 16 quarters. The position peaked at $38K in Q2 2021. 73 funds tracked by Wall St. Rank hold RCEL as of Q2 2026.

Ameritas Investment Partners reported no remaining Avita Medical position as of Q2 2026 after selling out during the quarter.
Ameritas Investment Partners sold 2,076 Avita Medical shares in Q2 2026, an estimated $7.68K.
Ameritas Investment Partners first reported a position in Avita Medical in Q2 2021 and held it in 16 quarters.
Ameritas Investment Partners's Avita Medical position peaked at $38K in Q2 2021.
73 funds tracked by Wall St. Rank held Avita Medical as of Q2 2026.

Based on Ameritas Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.